Start a live chat
1-800-870-4800
The cells that stop dividing —
and what they do
for the rest of their time.
A senescent cell is not simply a cell that has stopped working. It is a cell that has stopped dividing while remaining metabolically active — secreting a complex mix of inflammatory cytokines, proteases, and growth factors that alter the tissue environment around it. The accumulation of senescent cells with age is now understood to be one of the primary mechanisms driving the inflammaging examined in the earlier articles of this series, and the biology of senescence has become one of the most actively studied areas in aging research over the past two decades.
I
What a senescent cell is —
and how it gets that way.
Cellular senescence was first described by Leonard Hayflick in 1961 — the observation that normal human fibroblasts in culture stop dividing after a finite number of doublings, now known as the Hayflick limit. At the time, this replicative senescence was understood primarily as an artifact of cell culture, but subsequent research established that senescence is a genuine biological state with distinct molecular characteristics, occurring in living tissues across the lifespan and accumulating progressively with age. The Hayflick limit itself reflects the biology of telomere shortening: with each cell division, the telomeric caps at chromosome ends shorten, until they reach a critical length that triggers the DNA damage response — arresting the cell cycle and initiating the senescent state to avert the genomic instability that would result from further division with critically short telomeres. This connection between the telomere biology examined in the telomeres article and cellular senescence is one of the most direct molecular links between two of the primary hallmarks of aging.
But replicative senescence triggered by telomere shortening is only one route to the senescent state. Cells can also enter senescence in response to oncogene activation — a protective mechanism that arrests the proliferation of a potentially cancerous cell before it can accumulate further mutations. This oncogene-induced senescence (OIS) is thought to be a primary tumor-suppressive mechanism, and its impairment is associated with cancer progression. A third route is stress-induced senescence: cells exposed to sustained oxidative stress, DNA damage from ultraviolet radiation, certain chemotherapy agents, or the inflammatory signals of an already-senescent cellular neighborhood can enter senescence without telomere shortening or oncogene activation. This stress-induced pathway is particularly relevant to the discussion of aging tissue environments, where the inflammatory signals from existing senescent cells — the senescence-associated secretory phenotype, or SASP — can induce senescence in neighboring normal cells, creating a self-propagating wave of senescence through aging tissues.
The molecular identity of a senescent cell is defined by a consistent set of characteristics that distinguish it from quiescent (temporarily arrested) cells and from apoptotic cells. Senescent cells are permanently cell-cycle arrested — primarily through activation of the p53/p21 and p16/Rb tumor suppressor pathways, which place brakes on the cell cycle machinery that cannot be released by growth factors. They are resistant to apoptosis — upregulating anti-apoptotic proteins including Bcl-2 family members that protect them from programmed death signals. They display characteristic changes in chromatin organization (senescence-associated heterochromatin foci, or SAHF), increased lysosomal activity visible as elevated beta-galactosidase staining at pH 6 (a standard senescence marker), and the production of the SASP. It is the SASP — the cell's inflammatory secretome — that transforms an arrested, non-dividing cell into an active participant in tissue aging.
A senescent cell does not simply stop working.
It stops dividing while remaining fully active —
secreting a continuous stream of inflammatory signals
that alter the tissue environment
for every cell around it.
The SASP · Three Component Classes
The senescence-associated secretory phenotype —
what senescent cells release and why it matters.
The SASP is not a single molecule but a complex, cell-type-specific secretome containing hundreds of factors across three primary functional classes. Its composition varies with the type of senescence trigger, the cell type, and the tissue context — but its core inflammatory character is consistent across contexts.
The pro-inflammatory core of the SASP
Interleukin-6 (IL-6) and interleukin-8 (IL-8) are the most consistently elevated cytokines in the SASP across cell types and senescence triggers. IL-6 is a pleiotropic cytokine that drives inflammatory gene expression in neighboring cells, stimulates immune cell recruitment, and is one of the primary mediators of the systemic inflammatory signaling associated with inflammaging. IL-8 is a chemokine that recruits neutrophils and promotes tissue inflammation. Both are regulated by NF-κB — the master inflammatory transcription factor whose age-related activation is a central thread running through the inflammaging biology examined in the inflammaging article. Senescent cells are among the primary NF-κB-activating sources in aging tissue — making the senescent cell one of the most direct cellular contributors to the chronic inflammatory state that characterizes biological aging. All referenced research was conducted independently and did not involve specific Codeage products.
Proteases that degrade the extracellular matrix
Matrix metalloproteinases (MMPs) — a family of zinc-dependent endopeptidases that degrade extracellular matrix components — are among the most functionally consequential components of the SASP in connective tissues. Senescent cells in skin, tendon, joint, and vascular tissue secrete elevated levels of MMP-1, MMP-3, MMP-10, and other family members that progressively degrade the collagen and proteoglycan matrix of the tissue microenvironment. This MMP-driven ECM degradation connects the senescence biology directly to the structural collagen biology examined in the skin, joint, and tendon articles of this series: the age-related decline in connective tissue quality is not simply a function of reduced collagen synthesis and increased AGE cross-linking — it is also actively driven by the proteolytic activity of the accumulating senescent cell population in those tissues. The SASP MMPs alter tissue biomechanics, disrupt the structural environment that supports normal cell function, and contribute to the progressive loss of tissue organization characteristic of aged connective tissue.
SASP signals that alter stem cell and progenitor behavior
Beyond inflammatory cytokines and MMPs, the SASP contains growth factors — including hepatocyte growth factor (HGF), epidermal growth factor (EGF) family members, and transforming growth factor beta (TGF-β) — that influence the behavior of neighboring progenitor and stem cells in ways that are increasingly well-characterized in the aging biology literature. TGF-β from the SASP drives neighboring cells toward senescence (the paracrine senescence mentioned above) and inhibits stem cell proliferation in multiple tissue contexts. VEGF (vascular endothelial growth factor) in the SASP promotes abnormal angiogenesis. The growth factor component of the SASP reflects the biological origin of senescence as a wound-repair response — senescent cells were likely originally intended to appear transiently, signal tissue damage, recruit immune clearance, and then be eliminated. The pathological consequence of aging is that the immune clearance step — which works efficiently in young animals — becomes increasingly impaired, allowing senescent cells to accumulate rather than being removed after serving their acute signaling function.
II
How senescent cells accumulate —
and why the immune clearance system fails.
In young organisms, senescent cells are a transient presence. They appear in response to DNA damage, oncogene activation, or wounding; they signal tissue damage through the SASP; they recruit immune cells — primarily natural killer (NK) cells and macrophages — that recognize and eliminate them through a process that requires the expression of specific cell surface markers (NKG2D ligands) on senescent cells. The transient senescent cell is a useful biological actor: it arrests the potentially dangerous proliferation of a damaged cell, signals distress to the immune system, and participates in tissue repair and remodeling through SASP growth factors — then is cleared by immune surveillance. This controlled senescence and clearance cycle operates continuously throughout the body in young animals.
The problem with aging is that this cycle breaks down on both sides simultaneously. Senescent cell production continues — indeed, the accumulation of DNA damage, telomere erosion, and oxidative stress with age means that senescence induction is occurring at higher rates in aged tissue than in young tissue. But immune clearance becomes less efficient: NK cell cytotoxicity declines with age, macrophage senescent-cell recognition is impaired, and the aging immune system in general shows reduced capacity for the specific cellular recognition and elimination that senescent cell clearance requires. The result is net accumulation — more senescent cells entering the senescent state than are being removed — even though no individual senescent cell is technically immortal. This accumulation is documented across multiple tissues and species in the aging biology literature, with senescent cell burden increasing progressively from middle age onward in most tissues examined.
The mitochondrial biology examined in the mitochondria article intersects with senescence accumulation in two ways. First: dysfunctional mitochondria produce elevated ROS, which drives DNA damage, which promotes senescence induction. The self-reinforcing loop of mitochondrial aging — declining quality control, increasing ROS production, increasing mtDNA damage — is also a self-reinforcing loop for senescence induction in the cells housing those mitochondria. Second: senescent cells themselves develop characteristic mitochondrial dysfunction — elevated mitochondrial mass, elevated mitochondrial ROS production, impaired mitophagy — that both generates the energy needed for SASP production and contributes further to the oxidative stress environment of aging tissue. The NAD+ decline that impairs sirtuin activity also contributes to the impaired mitophagy that allows dysfunctional mitochondria to accumulate in senescent cells — closing another loop between the molecular pathways of aging examined across this series.
Senescence in Tissue · Four Contexts
Where senescent cell accumulation
has the most documented tissue consequences.
Skin is one of the best-studied tissues for senescent cell accumulation — both because it is accessible for biopsy and because the visual manifestations of skin aging make it clinically relevant. Dermal fibroblasts are the primary collagen-producing cells of the dermis, and their senescence — which is driven by UV exposure, oxidative stress, and replicative exhaustion over a lifetime of skin turnover — results in a specific functional transition: reduced collagen synthesis combined with elevated MMP production. A senescent dermal fibroblast produces less Type I and Type III collagen than a young fibroblast and simultaneously produces more MMP-1, MMP-3, and other collagenases that degrade the collagen it is no longer making. This dual change — reduced synthesis, increased degradation — is a major cellular contributor to the thinning dermis, loss of skin structural integrity, and wrinkle formation associated with skin aging. The SASP inflammatory signals from senescent fibroblasts also drive melanocyte dysfunction and epidermal barrier changes. All referenced studies were conducted independently and did not involve specific Codeage products.
Context: senescent fibroblast research in skin aging · MMP production and collagen turnover in aged dermis · UV-induced senescence and photoaging biology
Articular cartilage chondrocytes — the cells responsible for maintaining the Type II collagen and proteoglycan matrix of joint cartilage — are among the most vulnerable to senescence accumulation because cartilage is avascular and chondrocytes must survive in a low-oxygen, mechanically stressed environment for decades. Senescent chondrocytes in aged cartilage show characteristic SASP features — elevated IL-6, IL-8, and MMP production — that create a destructive microenvironment within the cartilage matrix. The senescent chondrocyte produces less new collagen and aggrecan (the primary load-bearing proteoglycan of cartilage) while simultaneously secreting proteases that degrade the existing matrix. Published histological studies of aged and osteoarthritic cartilage have documented elevated senescence markers — particularly p16 expression and beta-galactosidase activity — in chondrocytes from aged and damaged cartilage compared to young tissue. The connection between chondrocyte senescence and the joint aging biology examined in the joints article is one of the clearest examples of how senescence biology and structural collagen biology intersect.
Context: senescent chondrocytes in cartilage aging · p16 expression in aged cartilage · SASP and cartilage degradation research
Vascular endothelial cells — which line the interior of blood vessels and regulate vascular tone, permeability, and inflammation — accumulate senescence with age and at sites of disturbed flow (oscillatory or turbulent flow that produces higher oxidative stress). Senescent endothelial cells show reduced production of nitric oxide (a vasodilator), elevated expression of adhesion molecules that promote immune cell recruitment, and a SASP that creates a pro-inflammatory vascular microenvironment. Vascular smooth muscle cell senescence contributes to arterial stiffness — a clinically significant cardiovascular aging marker — through SASP-driven changes in the elastic properties of the vessel wall. Published research has found elevated senescence markers in vascular tissue from older adults compared to younger controls, and in atherosclerotic plaques compared to normal vascular tissue. The vascular senescence story connects directly to the cardiac energy biology of the creatine series: the coronary vasculature that supplies the heart depends on endothelial function that is compromised by senescence accumulation in the vessel wall.
Context: endothelial senescence and vascular aging · arterial stiffness and smooth muscle cell senescence · senescence markers in atherosclerotic tissue
Adipose tissue — and in particular the stromal vascular fraction and preadipocytes within it — accumulates senescent cells at a disproportionately high rate with age and with metabolic stress. The SASP of senescent adipose tissue cells is among the most pro-inflammatory documented across tissue types, with elevated IL-6, IL-8, MCP-1, and other cytokines that drive both local adipose tissue dysfunction and systemic inflammatory signaling. Published research using transgenic mouse models that allow selective elimination of senescent cells — the INK-ATTAC and p16-3MR systems — found that removing senescent cells from adipose tissue of aged mice was associated with measurable changes in adipose function and systemic metabolic markers. Adipose tissue is also the site where the p16-expressing senescent preadipocytes that have been most studied in translational senescence research accumulate — making it the tissue whose senescent cell population has the most direct evidence of functional consequence from published genetic and pharmacological clearance experiments.
Context: adipose senescence and metabolic aging · INK-ATTAC and p16-3MR transgenic senescence clearance models · preadipocyte senescence and systemic inflammation
The Senescence Numbers
Three figures that frame
the biology of senescent cell accumulation.
~1%
Estimated fraction of cells in young adult tissue that are senescent — rising substantially in aged tissue
Quantifying senescent cell burden in living tissue is technically challenging, but published estimates suggest that senescent cells constitute a small fraction of total cell number in young adult tissue — typically less than 1–2% in most tissues studied. With aging, this fraction rises — in some studies to 15–20% of cells in particularly affected tissues in elderly individuals. The biological impact of even a small fraction of senescent cells is amplified by the SASP: a cell secreting hundreds of inflammatory factors continuously exerts influence far beyond its own physical presence, affecting the dozens or hundreds of cells within its paracrine signaling range.
Fisetin
The naturally occurring flavonoid with the most published evidence as a senolytic compound in current research
Fisetin — a polyphenolic flavonoid found in fruits and vegetables including strawberries, apples, and onions — emerged from a 2018 Mayo Clinic screening of 10 flavonoids as the most effective senolytic (senescent-cell-clearing compound) of the group in cell culture and mouse models. Published studies have found that fisetin selectively promotes apoptosis in senescent cells by targeting the pro-survival Bcl-2 family proteins that senescent cells upregulate to resist cell death. Human clinical trials examining fisetin as a senolytic — including trials at Mayo Clinic in older adults — are ongoing, with published preliminary data documenting safety and early signals of cellular senescence marker changes.
2018
Year of the first human clinical trial of a senolytic drug combination, marking the translation of senescence biology into clinical research
The first published human clinical trial of a senolytic drug combination — dasatinib (a tyrosine kinase inhibitor used in oncology) and quercetin (a naturally occurring flavonoid), the "D+Q" combination — was published in 2018, marking the translation of the mouse model senolytic research into human subjects. The trial examined patients with idiopathic pulmonary fibrosis — a condition with documented elevated lung senescent cell burden — and found that intermittent D+Q administration was associated with measurable changes in circulating senescence biomarkers and preliminary functional signals. The field has since moved to examining senolytics in multiple age-related conditions, with dozens of registered clinical trials as of 2024.
III
Senolytics, senomorphics,
and the research direction this field has taken.
The translational potential of senescence biology rests on a distinction between two pharmacological approaches that the research literature now consistently distinguishes. Senolytics are compounds that selectively eliminate senescent cells — by exploiting the pro-survival pathways (primarily Bcl-2 family members) that senescent cells upregulate to resist apoptosis. Senomorphics (also called senostatics or SASP inhibitors) do not kill senescent cells but suppress the production or secretion of the SASP — reducing the inflammatory output of existing senescent cells without eliminating them. Both approaches have published evidence in model systems; their relative merits in clinical contexts are a subject of active investigation.
The senolytic research that has received the most attention involves naturally occurring compounds — primarily flavonoids — whose selectivity for senescent cells exploits the specific vulnerability created by their elevated Bcl-2 dependence. Quercetin — present in onions, capers, and many other plant foods — was identified in early Mayo Clinic screening as a senolytic, and has been studied extensively in the D+Q combination as well as in combination with fisetin and other flavonoids. Fisetin, as noted above, emerged from the same screening as the most active of the flavonoids tested. Navitoclax — a synthetic Bcl-2 inhibitor developed for oncology — is a more direct senolytic with established senescent cell-clearing activity but with dose-limiting toxicity (platelet reduction) that limits its utility as an aging intervention. The natural flavonoid senolytics are of interest specifically because their more modest Bcl-2 inhibition appears sufficient for the Bcl-2-dependent senescent cell while leaving non-senescent cells, which have less dependence on Bcl-2 survival signaling, largely unaffected. All research cited was conducted independently and did not involve specific Codeage products.
The senomorphic approach — suppressing the SASP without eliminating the senescent cell — overlaps substantially with the existing longevity compound literature. Rapamycin, which inhibits mTOR (the growth and translation control pathway examined in the longevity pathways article), is among the most consistently documented SASP suppressors in published research — mTOR activity is required for the translation of many SASP factors, and its inhibition substantially reduces SASP output in cell culture systems. NAD+ precursors and sirtuin activators also have published evidence of SASP modulation — SIRT1 activation suppresses NF-κB, the primary transcriptional driver of many SASP components, and NAD+ supplementation has been found to reduce SASP markers in several published studies of aged tissue. The convergence between the NAD+ biology of the mitochondria article, the mTOR biology of the longevity pathways article, and the senescence biology of this article is one of the more elegant aspects of the contemporary aging biology landscape — these are not separate stories but different vantage points on the same biology.
Senescent cells were originally
a transient tissue-repair tool.
What aging does is make them permanent —
by impairing the immune clearance
that was supposed to remove them.
Codeage · Cellular Longevity · Pillar 03
Formulations designed around
the senolytic flavonoid research.
Fisetin and quercetin formulations from Codeage — drawing on the published flavonoid senolytic research. Formulated without dairy, soy, or gluten. Non-GMO. Manufactured in the USA in a cGMP-certified facility with global ingredients.
Liposomal Fisetin — Cellular Longevity
Liposomal fisetin — the flavonoid with the most published senolytic evidence from the Mayo Clinic flavonoid screening, delivered via liposomal technology. Non-GMO. Made in the USA.
Join The Code →Liposomal NMNH+ Platinum — Quercetin Apigenin
NMNH alongside quercetin and apigenin — the D+Q research-studied flavonoid in a cellular longevity formula. Non-GMO. Made in the USA.
Join The Code →Codeage · The Longevity Code
Cellular longevity,
structured for the long view.
The Longevity Code is a four-pillar daily system — Pillar 03 speaks to the cellular biology this article describes.
Explore The Longevity Code →
